US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure

/PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company (NRx), today announced that the US Food and Drug Administration...

Related Keywords

United States ,Israel ,Americans ,Daniele Troy ,Eric Goldstein ,Jack Hirschfield ,Chaim Hurvitz ,Sherry Glied ,Jonathan Javitt ,Nrx Pharmaceuticals ,Phd Us Army ,Novartis ,Pfizer ,Source Nrx Pharmaceuticals ,Allergan ,Us Department Of Health ,Israel Institute For Biological Research ,Biomedical Advanced Research ,Human Services ,Drug Administration ,Prnewswire Nrx Pharmaceuticals ,United States National Security Advisor ,Development Authority ,Nrx Pharmaceuticals Inc ,Teva International Group ,Us Department Of Defense ,Us National Institutes Of Health ,Head Of Corporate Communications ,Emergency Use Authorization ,Data Safety ,Monitoring Board ,Chief Executive Officer ,Manufacturing Controls ,Quantum Leap Healthcare ,Data Safety Monitoring Board ,Serious Adverse Events ,Fast Track ,Medical Countermeasures ,Breakthrough Therapy Designation ,Special Protocol Agreement ,Biomarker Letter ,Israel Institute ,Chief Counsel ,United States National Security ,Securities Litigation Reform Act ,Corporate Communications ,